BiotechTube
Axoltis Pharma

Axoltis Pharma

Lyon, France· Est.
axoltis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Axoltis Pharma is a clinical-stage biotech company pioneering CNS regeneration therapies. Its lead asset, NX210c, is a therapeutic peptide with a dual mechanism of action targeting blood-brain barrier integrity and neuronal protection/function. The company has raised €18M, completed a Phase 1b trial, and is currently conducting a Phase 2 trial in Amyotrophic Lateral Sclerosis (ALS). Axoltis aims to address significant unmet needs in severe neurological disorders through its innovative peptide-based approach.

NeurologyNeurodegenerative Diseases

Technology Platform

Proprietary therapeutic peptide (NX210c) with a dual mechanism of action: improving blood-brain barrier integrity and providing direct neuronal protection/functional effects.

Opportunities

A positive Phase 2 readout in ALS could validate the platform, attract partnership or acquisition interest, and enable expansion into other large-market neurological disorders with BBB impairment, such as traumatic brain injury or stroke.
The high unmet need in neurology supports premium pricing for effective therapies.

Risk Factors

High binary risk on the ongoing Phase 2 ALS trial results.
The novel dual mechanism, while promising, is unproven in patients.
The company has a single-asset pipeline, creating significant concentration risk, and will require substantial additional capital to advance development.

Competitive Landscape

Competition in ALS is intense, with several approved therapies (Riluzole, Edaravone, Relyvrio, Qalsody) and numerous companies in clinical development. The broader neuroprotection/BBB repair space is also crowded with approaches from large pharma and biotech, though Axoltis's specific peptide mechanism may be differentiated.

More companies in Cell & Gene Therapy →More companies in France →